Citations

Clear

12617 citation(s) found for "Go, John R".

Vascular Abnormalities in the Hand and Wrist: State-of-the-Art Multimodality Imaging
Bretzman, John P. , Bookwalter, Candice, Bendel, Emily , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | October 29, 2026 | Volume: 46 | Issue: 11 | Pages: No page available

10.1148/rg.250210 | PMID 42955840 Get It

A thorough understanding of hand and wrist vascular anatomy and disease patterns, combined with strategic use of multimodality imaging, enables radiologists to diagnose vascular diseases, guide clinical management, and help preserve limb function.
Diagnostic approach and management strategy for patients with exertional rhabdomyolysis – Results from an international survey of healthcare professionals
Godtfeldt Stemmerik, Mads , Kruijt, Nick , Kleefeld, Felix , Laforêt, Pascal , Bhai, Salman , Liewluck, Teerin , Ravenscroft, Gianina , Vissing, John , Voermans, Nicol Cornelia

Mayo Clinic

Journal of Neuromuscular Diseases | October 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/22143602261493649 | PMID 42950351 Get It

Background Rhabdomyolysis is a complex and potentially life-threatening syndrome characterized by the rapid breakdown of damaged skeletal muscle. Despite its clinical significance, universally accepted diagnostic criteria and standardized management guidelines are lacking. Methods A cross-sectional online survey about the current diagnostic approach, assessment of risk factors and severity, and management of follow-up of rhabdomyolysis was conducted among clinicians across Europe, Australia, and the USA. Results Fifty-four respondents from 16 countries completed the survey. Results revealed considerable variability in hospital admission practices, and patient follow-up. Some agreement was found in the frequent use of genetic and neurophysiological testing in as diagnostic tools. The survey revealed no consensus on which CK-level would be considered cut-off levels for rhabdomyolysis. Conclusions The survey found little to no coherent approach to diagnosing, assessment of severity, nor follow-up of rhabdomyolysis among respondents who were primarily neurologists and pediatric neurologists. It highlights the need for international guidelines in the diagnostic process, treatment and follow-up of rhabdomyolysis as well as a universally agreed definition of rhabdomyolysis.
A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01
Borad, Mitesh J. , Busset, Michele Droz Dit , Javle, Milind , Shaib, Walid L. , Personeni, Nicola , Mody, Kabir , Bergamo, Francesca, Harris, William P., Damjanov, Nevena , Macarulla, Teresa , Brandi, Giovanni , Masi, Gianluca , Abou‐Alfa, Ghassan K. , Hálfdánarson, Þorvarður R. , Knox, Jennifer, Tam, Vincent C. , Bernat, Mathieu, Engelhardt, Marc , Friedmann, Silke, Häckl, Manuel, McKernan, Phil, Saulay, Mikael, Goff, Laura W. , Hollebecque, Antoine , Adeva, Jorge , Jeffry Evans, Thomas R. , Bridgewater, John , Foerster, Friedrich , Kendall, Stephan DiSean, Roth, Gaël , Cunningham, David, Vogel, Arndt , Niger, Monica , Mahipal, Amit , Mazzaferro, Vincenzo

Mayo Clinic

Hepatology | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001902 | PMID 42937546 Get It

Background & Aims: To evaluate safety and efficacy of FGFR1–3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements ( FGFR2 F ), mutations ( FGFR2 M ), or amplifications ( FGFR2 A ), previously treated with chemotherapy. Approach & Results: Open-label, non-controlled Phase 2 trial. Patients with advanced iCCA, ≥1 prior chemotherapy, and FGFR2 F (Substudy 1) or FGFR2 M /FGFR A (Substudy 2), received once-daily oral derazantinib 300 mg until disease progression, unacceptable toxicity, consent withdrawal or investigator decision to stop. Efficacy was assessed by central radiology review using RECIST v1.1. Primary endpoints were objective response rate (ORR; Substudy 1) and 3-month progression-free survival (PFS3; Substudy 2). Other endpoints were PFS, ORR (Substudy 2), disease control rate (DCR), duration of response (DOR), and overall survival (OS). In Substudy 1, ORR and DCR were 22.3% (23/103 partial responses) and 75.7%, respectively; median (95% CI) PFS was 8.1 (5.5,8.3) months, DOR was 6.5 (4.6,9.2) months, and OS was 17.2 (12.5,22.4) months. In Substudy 2, PFS3 was 63% (27/43), ORR was 9.3% (3 partial, 1 complete response), DCR was 69.8%, and OS was 11.9 (8.4,15.9) months. There were no Grade 4 or 5 drug-related events. FGFR inhibitor class-specific toxicities included drug-related hyperphosphataemia (38%, Grade 3: 3%) and dry eye (36%). Nail disorders (10%, any grade or causality), stomatitis (5%), retinal events (5%), and palmar-plantar erythrodysesthesia (1%) were infrequent. Conclusions: In previously chemotherapy treated, FGFR-inhibitor-naïve patients with iCCA harboring FGFR2 fusions, mutations, or amplifications, derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile.
Fatal Donor‐Derived Kaposi Sarcoma Diagnosed at Autopsy and Allograft Explant in Two Recipients From a Single Donor: The Case for Risk‐Based HHV‐8 Screening
McGrath, Nathan G. , Skaugen, John , Johnson, Bruce, Hage, Chadi A. , Alasfar, Sami , McCullough, Ann E. , Sigler, Rachel, Sanchez, Pablo G., Coster, Janalee N., Marayati, Firas, Vikram, Holenarasipur R. , Haidar, Ghady , Bartholow, Tanner

Mayo Clinic

Transplant Infectious Disease | October 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/tid.70344 Get It

Application of Optic Neuritis Diagnostic Criteria in Autoimmune Paraneoplastic CRMP5 Optic Neuropathy and Development of the “CRMP” Score
Dinoto, Alessandro , Cohen, Devon A , Cacciaguerra, Laura , Tisavipat, Nanthaya , Syc-Mazurek, Stephanie B , Lennon, Vanda A , Bhatti, M Tariq , Tajfirouz, Deena , Chodnicki, Kevin , Pittock, S J , Flanagan, E P , Chen, John J

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | October 21, 2026 | Volume: 13 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000200666 | PMID 42905998 Get It

Catheter‐Directed Interventional Devices for Pulmonary Embolism: A Maude Database Analysis of Adverse Events
Nandyal, Shreyas Raghavan , Gajjar, Rohan , Varma, Revati , Athmakuri, Krishna Saketh , Vij, Aviral

Mayo Clinic

Catheterization and Cardiovascular Interventions | October 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ccd.70948 | PMID 42902848 Get It

ABSTRACT Background Catheter‐directed therapies for acute pulmonary embolism (PE) are being adopted rapidly, yet real‐world safety data remain limited. Aims To characterize adverse events, device failure patterns, and mortality signals for three FDA‐cleared catheter‐directed PE platforms (EKOSONIC, INDIGO, and FlowTriever) using the FDA Manufacturer and User Facility Device Experience (MAUDE) database. Methods Medical device reports (MDRs) were downloaded from each device's PE clearance (2008, 2015, and 2018, respectively) through March 2026 and filtered by text to retain PE‐specific reports. Reports were classified by manufacturer, event type (death, injury, malfunction), device problem, and patient problem, and trends were assessed by calendar year. Results Of 2528 reports, 389 were PE‐specific (INDIGO 228 [58.6%], EKOSONIC 149 [38.3%], FlowTriever 12 [3.1%]), spanning 2009 to January 2026. There were 76 deaths (19.5%), 133 injuries (34.2%), and 180 malfunctions (46.3%). Annual death reports rose from 2023 (15 in 2023, 13 in 2024, 8 in 2025, and 3 in January 2026). Among 47 INDIGO deaths, 28 (59.6%) involved Lightning/Flash large‐bore catheters, and 36 (76.6%) carried a perforation‐, hemoptysis‐, tamponade‐, or extravasation‐related patient problem code. Separator wire break/fracture was the leading INDIGO device failure. EKOSONIC reports showed thrombolytic‐related bleeding, including intracranial or cerebral hemorrhage in 12 reports (8.1%). Conclusions MAUDE reports reveal distinct device‐specific safety signals: pulmonary artery perforation with large‐bore INDIGO aspiration catheters, and intracranial hemorrhage with EKOSONIC. Death reports increased from 2023 as mechanical thrombectomy use expanded. Absent procedural denominators, rates and causality cannot be inferred; findings support operator awareness, careful patient selection, and continued post‐market surveillance.
Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
Greenall, Sam A , Chen, Shengnan C , Alton, Gordon , Beaton, Graham , Casey, Mattie , Babic, Ivan , Tucci, Fabio C , Ravula, Satheesh B , Stein, Gregory D , Li, Yuchen , D'Souza, Rochelle , Kumar, Ashwani , Kittler, Ralf , Tuma, Ann C M, Sarkaria, Jann N , Gough, Daniel J , Stewart, Rodney A , Kesari, Santosh , Day, Bryan W , Johns, Terrance G

Mayo Clinic

No container title available | October 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.14.759257 | PMID 42995774 Get It

Background: Glioblastoma (GBM) remains uniformly fatal. The basic helix-loop-helix transcription factor OLIG2 is universally expressed in diffuse glioma, sustains the tumor-propagating stem-like fraction, and opposes p53-mediated genotoxic responses, but has historically been considered undruggable. We characterized CT-179, a brain-penetrant small-molecule OLIG2 inhibitor, as a candidate therapeutic for GBM. Methods: Target engagement was assessed by cellular thermal shift assay, differential scanning fluorimetry, crosslinking, and electrophoretic mobility shift assay. Anti-tumor activity was evaluated across eleven patient-derived GBM cell lines, in zebrafish oligodendrocyte precursor cell (OPC)-derived tumors, and orthotopic and subcutaneous GBM models, including combinations with radiotherapy plus temozolomide and with selective Bcl-2 family inhibitors. Results: CT-179 engaged OLIG2 and altered the conformation of dimerized OLIG2 on chromatin without preventing dimerization or fully displacing OLIG2 from DNA. CT-179 reduced OLIG2-positive OPCs and OPC-derived tumors in zebrafish and inhibited proliferation across all eleven GBM lines (IC50 < 360 nM), depleting the stem-like fraction and inducing apoptosis through mitotic catastrophe, mitotic slippage, or a hybrid response. RNA-seq across three patient-derived glioma stem cell lines identified β-tubulin gene isoforms as the most strongly CT-179-down-regulated transcripts at the early time point and showed correlated β-tubulin and OLIG2 expression in TCGA glioblastoma specimens. Combination with the Mcl-1 inhibitor S63845 or the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 produced greater-than-additive cytotoxicity. Oral CT-179 crossed the blood-brain barrier and extended median survival as a single agent across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 was associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 orthotopic xenografts. Combination of CT-179 with radiotherapy and temozolomide eliminated all GBM8 and 7 of 8 GBM4 subcutaneous xenografts without weight loss and significantly extended survival when combined with radiotherapy in MGMT-unmethylated GBM6 orthotopic xenografts (CT-179 administered intraperitoneally). Conclusions: CT-179 is a brain-penetrant inhibitor of an established GBM driver with single-agent and combination activity across several orthotopic models, supporting clinical development for GBM and translational evaluation in other OLIG2-dependent CNS malignancies.
Affective symptoms in focal epilepsy: A scoping review of localization and lateralizing findings
Sanchez-Boluarte, Sofia S , Acton, Emily K , Guevara-Lazo, S , Carrazana, Enrique , Freund, Brin E , Nascimento, Fábio A , Beniczky, Sándor , Tatum, William O

Mayo Clinic

Epileptic Disorders | October 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epd2.70438 | PMID 42873623 Get It

Abstract Emotional experiences during focal seizures are often misinterpreted as psychiatric disorders. We aimed to evaluate symptoms involving affective symptoms at seizure onset. We aimed to identify the most prevalent affective symptoms at seizure onset and characterize their localizing and lateralizing value. We performed a scoping review based on Preferred Reporting Items for Systematic reviews and Meta‐Analyses–extension for Scoping Reviews guidelines. A systematic search identified records from 4 databases: PubMed, Embase, CINAHL (via EBSCOhost), and Web of Science. Two reviewers independently screened titles/abstracts and full texts; discrepancies were resolved by consensus. This review focused on patients with focal seizures, as affective symptoms may occur in generalized epilepsies. The affective symptoms: fear, anxiety, panic, sadness, mystic, ecstatic, sexual, and mirth were identified, and semiology was evaluated in accordance with ILAE guidelines. Symptom onset, frequency, brain localization, and video‐EEG monitoring technique were evaluated to assess localization and lateralization of regional networks. Scalp EEG, invasive EEG recordings, and electrical stimulation were analyzed. A total of 1276 documents were identified, with 98 studies included for review. Fear was the most frequently reported ictal emotion, identified in 274 patients (66%), predominantly in temporal lobe epilepsy. Sadness and sexual, ecstatic symptoms were also consistently associated with temporal networks. Mirth was more frequently reported with frontal onset seizures. Evidence, primarily from Class IV studies, reported right hemispheric predominance for ecstasy, mystic, and sexual symptoms at seizure onset. Ictal affective symptoms at seizure onset yield localizing information. The limbic system, especially the temporal lobe, followed by the frontal lobe, was the most common site of origin. Fear was the most common spontaneous and electrically elicited symptom, followed by anxiety. While bi‐hemispheric lateralization occurred, right lateralization predominated. Recognizing paroxysmal affective symptoms as ictal phenomena may reduce misdiagnosis and aid presurgical evaluation in drug‐resistant focal epilepsy.
PET-Based Molecular Imaging in Neurodegeneration and Dementia: Current and Emerging Radiotracers
Gil, Nelson , Naik, Priyanka, Koran, Mary Ellen, Silverman, Daniel, Kako, Bashar , Chen, John

Mayo Clinic

Radiology Advances | October 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/radadv/umag046 | PMID 42927299 Get It

Abstract Positron emission tomography (PET)-based molecular imaging is a clinically important tool for the evaluation of dementia and other neurodegenerative disorders, using radiotracers that target specific molecular and pathophysiological processes. Fluorodeoxyglucose brain PET has historically supported neurodegenerative disorder evaluation through detection of characteristic patterns of regional glucose hypometabolism. In recent years, the molecular imaging of protein aggregates has taken on an increasingly important role. This is evident with the widespread clinical adoption of amyloid PET and early use of tau PET to provide diagnostic and prognostic information for patients with suspected Alzheimer’s disease. Additional classes of radiotracers relevant to neurodegenerative diseases are under active investigation, including those targeting neuroinflammation, synaptic density, and α-synuclein aggregates. We review the major classes of PET radiotracers for neurodegenerative diseases, describing their molecular mechanisms, diagnostic performance, and their current and emerging clinical roles in dementia evaluation. Case examples for clinically used tracers illustrate imaging features relevant to diagnosis and characterization of prognosis and treatment effect. Finally, we discuss early developments and current challenges in the development of theranostic approaches and novel radiotracers for neurodegenerative diseases.
Cost comparison of the ShangRing device versus Mogen clamp for early infant male circumcision in Sub-Saharan Africa
Punjani, Nahid, Zhang, Tenny R. , Basourakos, Spyridon P. , Barone, Mark A. , Christensen, Alice , Kigozi, Godfrey, Goldstein, Marc, Li, Philip S. , Mushlin, Alvin I. , Stover, John , Lee, Richard K.

Mayo Clinic

PLOS One | October 13, 2026 | Volume: 21 | Issue: 10 | Pages: e0360356

10.1371/journal.pone.0360356 | PMID 42868147 Get It

Introduction The World Health Organization (WHO) endorses male circumcision as an effective human immunodeficiency virus (HIV) prevention intervention in settings where the expected impact is greatest, including Sub-Saharan Africa. Data on cost implications of early infant male circumcision (EIMC) are limited. The ShangRing (SR) is a WHO pre-qualified device for circumcision. We sought to perform a comprehensive cost assessment alongside a randomized controlled trial (RCT) of the SR versus the standard of care Mogen clamp (MoC) for EIMC to enable future scale-up towards a cost-effective HIV prevention strategy. Methods We collected resource utilization and economic data as part of an RCT of infants aged 0–60 days old undergoing EIMC in Kenya, Tanzania, and Uganda. Cost data for both the SR and MoC included baseline facility costs, direct costs, and indirect costs. The Decision Makers Program Planning Tool v1.0 was used to perform a direct cost comparison of these two devices. The Goals model was used to compare the costs of EIMC in 2023 using the present value of money to circumcise an adolescent male 15 years from now. Results A total of 1,378 infant males underwent circumcision, 689 via SR and 689 via MoC. The overall cost of a single EIMC in Kenya, Tanzania, and Uganda were 61.30 United States Dollars ($), $47.14, and $64.59 respectively for the SR, and $56.38, $50.43, and $58.57 respectively for the MoC. In Kenya, EIMC would be less expensive based on nominal present costs in 2023 compared to waiting for adolescent circumcision at age 15 years in 2038. This finding is reversed in Tanzania and Uganda. Conclusions The overall cost of EIMC via SR versus MoC is comparable in an RCT. With scale-up utilizing lower level personnel, the cost of SR may be further reduced. The SR is an attractive alternative for future EIMC initiatives in Sub-Saharan Africa to further reduce HIV burden.